Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Market Closed 03-13 16:00:00 EDT

0.9735

+0.1645

+20.33%

盘后1.01

+0.0365+3.75%

19:59 EDT

High1.10	Low0.8425	Vol13.55M
Open0.8510	D1 Closing0.8090	Amplitude31.83%
Mkt Cap20.77M	Tradable Cap16.31M	Total Shares21.33M
T/O13.54M	T/O Rate80.87%	Tradable Shares16.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":0.9735,"timestamp":1773432000000,"preClose":0.809,"halted":0,"volume":13548522,"hourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":0.9735,"latestTime":"19:59 EDT","volume":198449,"amount":198494.444624,"timestamp":1773446398801,"change":0.0365,"changeRate":0.037494,"amplitude":0.081972},"delay":0,"changeRate":0.2033374536464771,"floatShares":16753800,"shares":21332900,"eps":-1.348531,"marketStatus":"Market Closed","change":0.1645,"latestTime":"03-13 16:00:00 EDT","open":0.851,"high":1.1,"low":0.8425,"amount":13536000.4559676,"amplitude":0.318294,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.348531,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":0.809,"preHourTrading":{"tag":"盘前","latestPrice":0.8317,"preClose":0.809,"latestTime":"09:28 EDT","volume":106614,"amount":88648.16141484,"timestamp":1773408513394,"change":0.0227,"changeRate":0.028059,"amplitude":0.074166},"postHourTrading":{"tag":"盘后","latestPrice":1.01,"preClose":0.9735,"latestTime":"19:59 EDT","volume":198449,"amount":198494.444624,"timestamp":1773446398801,"change":0.0365,"changeRate":0.037494,"amplitude":0.081972},"volumeRatio":0.25620525661611215},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2619416621","title":"Longeveron Inc. Files Initial Beneficial Ownership Statement for CEO Stephen H. Willard","url":"https://stock-news.laohu8.com/highlight/detail?id=2619416621","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619416621?lang=en_us&edition=fundamental","pubTime":"2026-03-14 08:59","pubTimestamp":1773449969,"startTime":"0","endTime":"0","summary":"Longeveron Inc. filed an initial statement of beneficial ownership  naming Willard Stephen H as Chief Executive Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260314:nNDL8lRyJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2618321561","title":"Longeveron Inc. to report full-year 2025 financial results and host conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2618321561","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618321561?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:05","pubTimestamp":1773320742,"startTime":"0","endTime":"0","summary":"Longeveron will report full-year 2025 financial results on March 17, 2026 after the U.S. financial markets close. The company will host a conference call and webcast on March 17, 2026 at 4:30 p.m. ET, accessible via Click Here. A “Call me” registration link is available at Click Here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3Cnkly:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4588","LGVN","NDAQ","BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4585","BK4112","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2618997308","title":"Longeveron closes USD 15 million private placement of shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2618997308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618997308?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:18","pubTimestamp":1773260288,"startTime":"0","endTime":"0","summary":"Longeveron closed a private placement for up to USD 30 million in gross proceeds, priced at-the-market under Nasdaq rules. The initial closing raised about USD 15 million in gross proceeds, led by Coastlands Capital with participation from Janus Henderson Investors. Longeveron issued 6.01 million Class A shares at USD 0.52 per share and Series A non-voting convertible preferred stock convertible into 22.83 million Class A shares. The company may receive up to an additional USD 15 million in gross proceeds subject to milestone-driven conditions tied to its Phase 2b ELPIS II trial in HLHS and share price. Longeveron also agreed to sell investors an interest in 50% of proceeds from any future sale of a Rare Pediatric Disease Priority Review Voucher related to its HLHS program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL6nwC9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054578231.USD","LGVN","IE00BGHQF748.EUR","BK4135","BK4139","IE00B64PRP62.GBP","JHG","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2618739449","title":"Press Release: Longeveron Announces Closing of Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618739449","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618739449?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259500,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement was led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory development of laromestrocel, working capital and other general corporate purposes. B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","LGVN","R","BK4139","BK4132","BK4232","AD","BK4022","BK4150","MSC"],"gpt_icon":0},{"id":"2618892538","title":"3 Penny Stocks to Watch Now, 3/11/26","url":"https://stock-news.laohu8.com/highlight/detail?id=2618892538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618892538?lang=en_us&edition=fundamental","pubTime":"2026-03-11 22:11","pubTimestamp":1773238260,"startTime":"0","endTime":"0","summary":"Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3 Penny Stocks to watch on March 11, based on TipRanks’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-3-11-26?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4175","BK4139","LGVN","ATPC","INKT"],"gpt_icon":0},{"id":"2618095537","title":"Longeveron prices 6.01M shares at 52c in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618095537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618095537?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:16","pubTimestamp":1773148569,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) entered into a definitive agreement with certain institutional and accredited investors for up to approximately $30M in gross pro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-prices-6-01m-shares-at-52c-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-prices-6-01m-shares-at-52c-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2618953902","title":"Press Release: Longeveron Announces Private Placement of up to $30 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953902?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:01","pubTimestamp":1773147660,"startTime":"0","endTime":"0","summary":"-- $15 million upfront with a milestone-driven potential additional $15. million related to the Company's anticipated pivotal clinical trial in. Hypoplastic Left Heart Syndrome  priced at the market under Nasdaq. -- Private placement led by Coastlands Capital with participation from Janus. -- Initial proceeds extend cash runway into 4Q26, past the anticipated. pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million.H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.The Company intends to use the net proceeds from the financing, together with its existing cash and cash equivalents, for funding for its ongoing clinical and regulatory","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","MSC","BK4232","R","BK4022","BK4575","LGVN","BK4150","BK4139"],"gpt_icon":0},{"id":"2614031808","title":"Longeveron reports Phase 2b trial results showing laromestrocel improves age-related frailty in Cell Stem Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2614031808","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614031808?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035512,"startTime":"0","endTime":"0","summary":"Longeveron Inc. reported that results from its Phase 2b randomized, dose-finding clinical trial of intravenous laromestrocel , an investigational allogeneic mesenchymal stem cell therapy, were published in the journal Cell Stem Cell. The study  enrolled 148 ambulatory individuals with age-related frailty and evaluated physical functioning and patient-reported outcomes. Longeveron stated that laromestrocel was associated with dose- and time-dependent increases in the 6-minute walk test compared with placebo, including a 63.4-meter improvement at month 9 , and reported associations with PROMIS Physical Function scores and changes in soluble TIE-2 as a potential biomarker. The results have already been presented in the form of a peer-reviewed publication.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL4NQXRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BGHQF748.EUR","NDAQ","BK4112","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LGVN","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","BK4139","IE00B64PRP62.GBP","BK4585","BK4588"],"gpt_icon":0},{"id":"2614318320","title":"Longeveron® Results of Phase 2B Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients With Age-Related Frailty Published in Cell Stem Cell","url":"https://stock-news.laohu8.com/highlight/detail?id=2614318320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614318320?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:05","pubTimestamp":1772035500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUABV2H8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2611196210","title":"Longeveron Appoints New CEO Amid Cost-Cutting Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2611196210","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611196210?lang=en_us&edition=fundamental","pubTime":"2026-02-14 06:23","pubTimestamp":1771021404,"startTime":"0","endTime":"0","summary":"Longeveron ( ($LGVN) ) has provided an update. On February 9, 2026, interim CEO Than Powell resigned from his temporary role at Longeveron but rema...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/longeveron-appoints-new-ceo-amid-cost-cutting-initiatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/longeveron-appoints-new-ceo-amid-cost-cutting-initiatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN","US7Y.BOND","TMF","US12M.BOND","BK4588","BK4585","US2Y.BOND","US5Y.BOND","US6M.BOND","US10Y.BOND","BK4096","US3Y.BOND","US30Y.BOND","TLTW"],"gpt_icon":0},{"id":"2611195871","title":"Longeveron Appoints Stephen Willard as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611195871","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611195871?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:43","pubTimestamp":1771019027,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) said late Friday it named Stephen Willard as chief executive officer, effective earlier this week, succeeding interim CEO Than Powell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","US6M.BOND","BK4096","US12M.BOND","BK4585","US2Y.BOND","US3Y.BOND","US30Y.BOND","US5Y.BOND","BK4139","TMF","US10Y.BOND","LGVN","TLTW","US7Y.BOND"],"gpt_icon":0},{"id":"2611193186","title":"Longeveron Names Stephen H. Willard as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193186","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193186?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:30","pubTimestamp":1771018210,"startTime":"0","endTime":"0","summary":"Longeveron Inc. has appointed Stephen H. Willard as Chief Executive Officer, effective February 11, 2026. He succeeds Than Powell, who served as interim CEO and will continue supporting the company during the leadership transition and ongoing business development activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL53pWJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014005.SGD","LU2210150020.SGD","LGVN","LU0314104364.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","BK4139","IE00BKPKM429.USD","BK4112","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2611193190","title":"Longeveron Inc - Than Powell Steps Down as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193190?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:30","pubTimestamp":1771018200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUABKNTGQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2611019315","title":"Longeveron Inc:  Phase 2B Clinical Trial in Hypoplastic Left Heart Syndrome Anticipated in Q3 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2611019315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611019315?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:30","pubTimestamp":1771018200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUABKNTGQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2611193481","title":"Press Release: Longeveron(R) Appoints Stephen H. Willard as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193481","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193481?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:30","pubTimestamp":1771018200,"startTime":"0","endTime":"0","summary":"private sectors as CEO of multiple biotechnology and pharmaceutical firms,with an impressive history of delivering significant fundraises and. -- Corporate focus on delivering top-line results from the pivotal Phase 2b. Roger Hajjar, MD, Chair of the Board's Nominating and Corporate Governance Committee, commented, \"On behalf of the Board and management team, I want to thank Than for his significant contributions over the past six months, stepping in to provide effective leadership and stability through this transition. We would also like to welcome Steven to his new role. We believe his extensive strategic operations and executive leadership experience will help drive Longeveron's future success.\". Mr. Willard, CEO, commented, \"This is an extraordinary time for Longeveron and our stem cell therapy laromestrocel. It is an exciting opportunity to be able to join a company with three development programs at the stage of pivotal clinical trials. I look forward to working with the Longever","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MSC","LGVN","BK4232","BK4132","R","BK4139","AD","BK4575","BK4022"],"gpt_icon":0},{"id":"2609309579","title":"Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage","url":"https://stock-news.laohu8.com/highlight/detail?id=2609309579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609309579?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:21","pubTimestamp":1770301261,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) supports and applauds Congress passing the Mikaela Naylon Give Kids a Chance Act. The Mikaela Naylon Give Kids a Chance Act reaut...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-applauds-mikaela-naylon-give-kids-a-chance-act-passage-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-applauds-mikaela-naylon-give-kids-a-chance-act-passage-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2609060713","title":"Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2609060713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609060713?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:15","pubTimestamp":1770300900,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233093/0/en/Longeveron-Applauds-Passage-of-the-Mikaela-Naylon-Give-Kids-a-Chance-Act-and-Reauthorization-of-Rare-Pediatric-Disease-Priority-Review-Voucher-Program.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4575","MSC","LGVN","BK4150","BK4139","BK4132"],"gpt_icon":0},{"id":"2607503371","title":"Longeveron granted Japan patent for potency assay methods for MSCs","url":"https://stock-news.laohu8.com/highlight/detail?id=2607503371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607503371?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:21","pubTimestamp":1769696468,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the Japan Patent Office, JPO, has granted a patent covering potency assay methods for assessing human mesenchymal ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-granted-japan-patent-for-potency-assay-methods-for-mscs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-granted-japan-patent-for-potency-assay-methods-for-mscs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2607033935","title":"Longeveron Granted Japan Patent for Potency Assay Methods for Human Mesenchymal Stem Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2607033935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607033935?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:15","pubTimestamp":1769696109,"startTime":"0","endTime":"0","summary":"Longeveron Inc. has been granted a patent by the Japan Patent Office covering potency assay methods for assessing human mesenchymal stem cells  derived from various sources, including bone marrow, adipose tissue, peripheral blood, and others, as well as MSCs differentiated from induced pluripotent stem cells. The patent, titled \"Potency Assay\" , provides protection in Japan through April 20, 2041, assuming all annuity fees are paid. This issuance expands Longeveron's international patent portfolio, supporting its clinical programs and products.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is solely responsible f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL64VmFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","BK4588","LU0314104364.USD","BK4139","LGVN","BK4112","LU2095319765.USD","IE00BKPKM429.USD","NDAQ","BK4585","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2606246650","title":"Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246650","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606246650?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:21","pubTimestamp":1769437284,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that the U.S. Food and Drug Administration has granted Longeveron a Type C meeting at the end of March to prepare for t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-granted-fda-type-c-meeting-ahead-of-elpis-ii-data-readout-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-granted-fda-type-c-meeting-ahead-of-elpis-ii-data-readout-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":1.013},{"period":"1month","weight":0.7988},{"period":"3month","weight":0.599},{"period":"6month","weight":0.236},{"period":"1year","weight":-0.4064},{"period":"ytd","weight":0.9239}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052773},{"month":3,"riseRate":0.5,"avgChangeRate":0.172908},{"month":4,"riseRate":0.4,"avgChangeRate":-0.129651},{"month":5,"riseRate":0.4,"avgChangeRate":-0.141174},{"month":6,"riseRate":0.8,"avgChangeRate":0.122312},{"month":7,"riseRate":0.6,"avgChangeRate":0.185232},{"month":8,"riseRate":0,"avgChangeRate":-0.329414},{"month":9,"riseRate":0.2,"avgChangeRate":-0.104571},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.29104},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}